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Abstract
Introduction: The mechanisms by which selective serotonin re-uptake inhibitors (SSRI) act in depressed patients remain
unknown. The serotonergic neurotransmitter system and the hypothalamic-pituitary-adrenal (HPA) system may interact. The
aim of the AGENDA trial was to investigate whether long-term intervention with SSRI versus placebo affects the cortisol
response in the dexamethasone corticotropin-releasing hormone (DEX-CRH) test in healthy first-degree relatives to patients
with major depressive disorder (MDD).
Methods: Eighty healthy first-degree relatives to patients with MDD were randomized to escitalopram 10 mg versus
matching placebo daily for four weeks. The primary outcome measure was the intervention difference in the change of the
total area under the curve (CorAUCtotal) for plasma cortisol in the DEX-CRH test at entry to after four weeks of intervention.
Results: Change in CorAUCtotal showed no statistically significant difference between the escitalopram and the placebo
group, p=0.47. There were large intra- and inter-individual differences in the results of the DEX-CRH test. There was
statistically significant negative correlation between the plasma escitalopram concentration and change in CorAUCtotal,
rho=20.41, p=0.01. Post-hoc analyses showed a statistically significant interaction between age and intervention group
and change in log CorAUCtotal.
Conclusion: The present trial does not support an effect of escitalopram 10 mg daily compared with placebo on the HPA-
axis in healthy first-degree relatives to patients with MDD. Increasing levels of escitalopram tended to decrease the HPA-
response in the DEX-CRH test and this effect increased with age.
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Introduction
Depression is associated with an altered function of the
neuroendocrine feedback regulation of the hypothalamic-pitui-
tary-adrenal (HPA) axis, including cortisol escape from dexameth-
asone suppression and increased cortisol responses to the
dexamethasone corticotropin releasing hormone (DEX-CRH) test
[1]. Previous studies have shown that even healthy first-degree
relatives to patients with major depressive disorder (MDD) have an
abnormal HPA response to the DEX-CRH test, with an
intermediary response when compared to healthy controls and
patients with major depression [2]. Furthermore, salivary cortisol
has been shown to be increased in individuals with a family history
of MDD as compared to healthy individuals without a family
history of MDD [3–5]. Intervention with a single dose of a
selective serotonin re-uptake inhibitor (SSRI) has been found to
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corticosteroid levels in healthy humans [8–12]. In rats plasma
levels of HPA-axis hormones, corticosterone and adrenocortico-
tropic hormone (ACTH), decreased after 15 days intervention
with citalopram [13]. It is well known that selective serotonin
reuptake inhibitors (SSRI) have an effect on depression [14,15].
Studies of depressed patients have suggested that improved
hypothalamic-pituitary-adrenal (HPA) system regulation (de-
creased DEX-CRH test response) is associated with beneficial
treatment response [16]. Whether this is a direct effect of
treatment with antidepressants or a consequence of improvement
in depressive symptoms is unclear.
Robins and Guze described five phases in the development of a
valid classification of psychiatric illness: clinical description,
laboratory studies, delimitation from other disorders, follow-up
studies and family studies [17]. Later, response to treatment was
added as a sixth phase [18]. Recently, the endophenotype concept
has emerged as a strategic tool in neuropsychiatric research [19].
Endophenotypes are quantifiable components in the ‘‘genes-to-
behaviours’’ pathways distinct from psychiatric symptoms [19]. In
parallel with the classification of psychiatric diseases, endopheno-
types are validated by specificity, state independence, heritability,
familial association, co-segregation, and biological and clinically
plausibility [20].
Several possible endophenotypes have been proposed in
affective disorders, including stress regulation, cognition, neurot-
icism, depression and anxiety symptoms [20]. Pharmacological
anti-depressants may have an effect on endophenotypes in healthy
persons with a family history of depression. We hypothesized that
treatment response could be added to the validation of possible
endophenotypes for depression.
It is unclear whether antidepressants have an effect on potential
endophenotypes for depression in healthy first-degree relatives of
patients with depression, thus it has never been investigated
whether this deregulated HPA axis in healthy individuals with a
family history of MDD may become normalized by antidepres-
sants [21]. The AGENDA (Associations between genepolymorph-
isms, endophenotypes for depression and antidepressant inter-
vention) trial [22] is the first to investigate the effect of long-term
(four weeks) daily administration of a selective serotonin re-uptake
inhibitor (SSRI) versus placebo on the HPA-axis in healthy first-
degree relatives to patients with MDD [21]. The function of the
HPA-axis was investigated using the DEX-CRH test. The aim of
the present trial was to test the hypothesis that an intervention with
SSRI as compared with placebo decreases the cortisol response in
the DEX-CRH test for first-degree relatives of patients with
MDD.
The ultimate translational value of a experimental trial like the
ADENDA trial of high-risk individuals is to increase our
understanding of the patogenesis of illness.
Materials and Methods
The AGENDA trial was investigator initiated and designed.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. It was conducted as a participant-, investigator-,
observer-, and data-analyst-blinded trial. During the trial the
participants received either escitalopram 10 mg/day or placebo
for a period of four weeks. The trial protocol was published ahead
of trial completion [22]. The trial was conducted from July 2007
until July 2009 at the Department of Psychiatry, Rigshospitalet,
Denmark as part of the Centre for Pharmacogenomics, University
of Copenhagen, Denmark. The trial was conducted and
monitored in accordance with the International Conference on
Harmonization for Good Clinical Practice guidelines and the
Declaration of Helsinki 2002 (www.wma.net/e/policy/b3.htm).
The Local Ethics Committee (De Videnskabsetiske Komite ´er for
Københavns og Frederiksberg Kommuner, Københavns Kom-
mune) approved the trial: H-KF 307413.
Probands
Probands were patients with MDD from psychiatric in- or out-
patient hospital contact in Denmark who participated in ongoing
studies at the Department of Psychiatry, Rigshospitalet. Their
diagnoses were validated by face-to-face interviews including the
semi-structured interview Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) [23] by trained medical doctors [24].
The probands were asked to permit that the first author contacted
their adult children and siblings.
Participants
Participants were recruited as healthy first-degree relatives
(adult children or siblings) of the probands described above.
Individuals meeting the inclusion criteria and none of the
exclusion criteria were enrolled in the trial, Table 1.
Assessments
The first part of the assessment was a telephone interview of the
potential participants. The individuals eligible were scheduled to
meet at the clinic on two different days both before and following
four weeks of intervention. On the first day the participants gave
written informed consent after details of the trial were explained.
Diagnoses were ascertained by the SCAN interview and the
structured Clinical Interview for DSM-IV Axis II Personality
Disorders [25]. The DEX-CRH test was performed at entry and
following four weeks of intervention. Further assessment included
information on family history of psychiatric disorders, ratings of
mood using the 17-item Hamilton Depression Rating Scale
(HAM-D) [26] and 14-item Hamilton Anxiety Scale [26], various
socio-demographics, height, weight, routine blood tests, and, a
pregnancy test for women. Furthermore, following four weeks of
intervention blood was drawn for measurements of plasma
escitalopram, and the UKU Side Effect Rating Scale [27] was
applied by the principal investigator.
Interventions
The participants were randomized to self-administer a single
dose of either escitalopram 10 mg or placebo daily for four weeks.
The manufacturer provided escitalopram and placebo tablets. The
tablets were identical in appearance, color, smell, and solubility
allowing for blinding of the assignment to intervention or placebo.
An independent pharmacist packed the identically appearing
blister packages containing escitalopram or placebo and then
sealed, and numbered the packages according to a randomization
list provided and concealed by the Copenhagen Trial Unit (CTU).
On completion of the four weeks of intervention participants
entered a five-day down-titration period to nil medication.
Compliance to the protocol was sought by making weekly
telephone calls to the enrolled participants. The participants were
asked at the end of the trial, if they had missed taking any tablets.
Randomization
CTUperformed thecentralized computerizedrandomization 1:1
by telephone to secure adequate allocation sequence generationand
allocationconcealment.Randomization wasstratifiedinblocksof 6,
The Effect of SSRI on HPA-Axis in Healthy - A RCT
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21224by age (18–31 and 32–60 years), and sex. Only the data manager
knew the block size.
Blinding
All trial personnel and participants were blinded to the
packaging of the trial drug, and blinding was maintained
throughout monitoring, follow-up, assessment of outcomes, data
management, data analyses, and conclusions drawn [28]. At the
assessment after four weeks intervention, each participant and the
principal investigator (UK) made a guess as to which intervention
the participant had received. The agreement between the actual
intervention and the guesses was estimated to assess the degree to
which blinding had been demasked, thus k: ,0 no; 0.0–
0.20=slight; 0.21–0.40=some; 0.41–0.60=moderate; 0.61–
0.8=substantial; 0.81–1.00=almost complete demasking.
Analysis of plasma escitalopram
The extraction and quantitation of escitalopram was carried out
on an ASPECXL combined with a high-pressure liquid chroma-
tography system, both from Gilson, Villiers le Bell, France.
Lower and upper limits of quantitation were 10 nmol/l and
3,600 nmol/l. The interassay coefficients of variation ranged from
5.5% to 8.4% and trueness ranged from 93.2% to 103.0% within
the measurement range.
Change in hormone responses to the combined DEX-
CRH test
Cortisol and ACTH levels in response to the combined DEX-
CRH test were measured before and after four weeks of
intervention. The application of this combined DEX-CRH-
challenge requires individuals to take 1.5 mg dexamethasone
(DEX) at 23:00 h orally the previous night. On the day of the test,
100 micrograms human CRH are administered to the subjects
under study at 15:00 h intravenously as a bolus, and blood samples
for the determination of plasma cortisol and ACTH are drawn
every 15 min from 14:00 h to 18:00 h. [2]. The participants had a
light lunch at noon at the day of the CRH challenge. A trained
bio-technician and trained medical students conducted the tests
under the supervision of the principal investigator.
Analyses of cortisol and ACTH
Hormones were analyzed at the Department of Clinical
Biochemistry, Rigshospitalet. Plasma cortisol was measured using
a competitive electro chemiluminescense immuno assay (ECLIA)
(Roche Diagnostica Cortisol) and Modular analytics E170
(Roche). Lower and upper limits of quantiation were 1.0 and
17,500 nmol/l. The interassay coefficients of variation were 4.7%
and 5.6% at 116 and 968 nmol/l, respectively. Plasma ACTH was
measured using a sandwich chemiluminescense immunometric
method (ACTH, Immulite Siemens DPC) and Siemens Immulite
2000. Lower and upper limits of quantitation were 1.0 and
556 pmol/l. The interassay coefficients of variation were 7.6%
and 6.1% at 7 and 106 pmol/l, respectively.
In accordance with Modell et al, cortisol and ACTH responses
were calculated according to the trapezoidal rule as the total area
under the curve (AUCtotal) from administration of CRH at 15:00h
to the last measure at 18:00h [2]. The plasma cortisol (COR)
BASAL was estimated as the mean of the baseline measurements
before the administration of CRH. CorPEAK was estimated as the
highest plasma cortisol measurement following CRH administra-
tion. The primary outcome measure was the difference between
the intervention groups change of the total area under the curve
(CorAUCtotal) for plasma cortisol in the DEX-CRH test at entry to
after four weeks of intervention, DCorAUCtotal. It was calculated
by subtracting CorAUCtotal at four weeks from the CorAUCtotal
determined immediately before the initiation of the intervention.
Similarly, D was calculated for ACTH AUCtotal, CorBASAL, and
CorPEAK. The DCorAUCtotal was chosen since CorAUCtotal was
statistically significant in the Modell study.
Statistical methods
The sample size estimation and the pre-established data analysis
plan have previously been described [22]. The power calculations
were hypothetical since the effect of SSRI on the DEX-CRH test
in healthy has not been investigated in prior trials [22]. Thus, the
power calculation was merely guided by a previous case control
study in which the difference between healthy with and without a
family history of MDD was regarded as a possible relevant
difference [2], reflecting the hypothesis that the increased cortisol
response to the DEX-CRH test in individuals with a family history
of MDD would decrease, as a result of the SSRI intervention, to
the level of the cortisol response measured in healthy without a
family history of MDD (see below).
Data from all randomized participants were analyzed, including
those with missing data on the DEX-CRH test. The primary
outcome measure was not normally distributed, and could not be
transformed into a normal distribution. Thus, the outcome in the
Table 1. Criteria for inclusion and exclusion in the AGENDA trial.
Inclusion criteria Exclusion criteria
Healthy individual of both sexes* Somatic illness or other handicap, which made participation in the trial impossible
Offspring or sibling of an ethnic Dane, with a history of psychiatric
in- or outpatient care with a diagnosis of major depressive disorder
and who later had the diagnosis verified in a SCAN interview at the
Department of Psychiatry Rigshospitalet, Denmark 2004–2009
Daily intake of drugs interfering with corticosteroids or escitalopram, including birth
control pills or any kind of corticosteroids
Aged 18–60 years. Women were **preferably in lutheal phase menstrual
cycle or post-menopausal at the time of randomization
Hypersensitivity to escitalopram, dexamethasone, or human corticotropin-releasing
hormone
Born in Denmark Former medical or psychological treatment for diseases in the affective or
schizophrenic spectrum
European parents and grandparents Current abuse of alcohol or psychotropic medication
Able and willing to sign informed consent Pregnancy or breastfeeding
*A total of 6 participants with stable treated medical conditions were included: hypertensio arterialis (3), pancreatitis antea (1), hypothyroidism (1) and acne vulgaris (1).
**Women were in lutheal phase or postmenopausal at the times of assessments.
doi:10.1371/journal.pone.0021224.t001
The Effect of SSRI on HPA-Axis in Healthy - A RCT
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21224intervention and the placebo groups were compared by the Mann-
Whitney test.
Regression analyses (using the general linear univariate model)
were done including the primary outcome as the dependent
variable and a treatment indicator (escitalopram versus placebo)
plus design variables, including stratification variables [29] age,
sex, HAM-D total score at entry, body mass index at entry,
number of daily cigarettes, and concentration of escitalopram in
plasma as independent variables Exploratory analyses (including
the primary outcome, the treatment indicator and one design
variable) were first done to select the design variables (if any) to be
included in the final analysis (if any). If the explorative analysis of a
design variable had a p-value.0.1 the design variable was not
included in the final analysis.
In these analyses the residuals followed a Gaussian distribution
with reasonable approximation (the distributions were reasonably
symmetric but most of them deviated significantly from a Gaussian
one as judged from the Shapiro Wilks test).
Initially, the drug level measured in each participant was not
included in the models as to keep the statistician and investigators
blinded. Lastly, after all other analysis had been done and
conclusions drawn, analyses for the effect of drug-level were
performed.
An explorative analysis (not protocol specified) included the
natural log of the ratio between the total cortisol AUC measured
after intervention and the total cortisol AUC measured before the
intervention (ln(deltaAUC)), the treatment indicator and the
design variables. Ln(deltaAUC) followed the Gaussian distribution
with good approximation. We first analysed if there was a
treatment effect of this outcome measure in a regression analysis
including ln(deltaAUC) and the treatment indicator (I). Then we
examined if any of the design variables interacted with the
treatment. Each analysis included ln(deltaAUC), the treatment
indicator (I), one design variable (D) and I*D.
Explorative analyses were also done using a mixed model see
e.g. Sullivan et al. [30] and Winkel et Zhang [31].
The modeling program (R-program) not including the inter-
vention indicator was developed using the p-cortisol data
measured at the start of the trial. The intervention indicator was
then included (see below) in this program, which was applied on
the p-cortisol values measured in the two intervention groups at
the end of the trial.
Initial analyses showed that it was necessary to use logarithmic
values to obtain homogeneity of variance. The p-cortisol was
measured 17 times in each subject. Figure 2 shows the mean of
ln(p-cortisol/unit) as a function of time in each of the two groups.
It appears that the relationship between mean values and time (t) is
linear with reasonable approximation within each of the intervals
[1#t#5], [6#t#9] and [10#t#17] in the following referred to as
A, B and C, respectively. The model is as follows:
Ln p   cortisol=unit ðÞ ~azbtzcIAzdIBzeICzft:
IAzgt : IBzht : IC
where a, b, c, d, e, f, g and h are coefficients (‘fixed effects’), to be
estimated. IA is an indicator equal to 1, if t is within the time
interval A and 0 otherwise. IB and IC are similarly defined; a is an
intercept, b is the common slope of p-cortisol as a function of time.
The indicators define the level of each of the three linear functions
corresponding to the above-defined three time intervals. The
interaction (symbolized by ‘:’) between t and the indicators serve to
modify the slope of each of the three linear functions relative to the
common slope b.
Significant reductions of the variability were obtained by
supplementing the model with random effects (subject specific
coefficients) corresponding to all of the above fixed effects.
An analysis of the variance of the residuals showed inhomoge-
neity of the variances in that the variance was not the same in the
three groups defined by the three time intervals This effect was
therefore included in the final model. The residuals were not
significantly correlated.
Using the subject specific random effects in conjunction with the
fixed effects personalized models of the p-cortisol versus time curve
may be developed and used to follow a subject as his/her own control.
In the present context we utilized the model by introducing an
intervention indicator (arm) in it (main effect and interactions, i.e.
the terms arm, arm:t, arm:IA arm:IB etc were added to the
model). We then tested if any of the corresponding coefficients
differed significantly from 0 to see if the intervention influenced
the three linear functions in any way.
In correlation analyses where the data did not follow Gaussian
distributions we used the Friedman non-parametric test in place of
the Pearson correlation test.
All analyses of the primary outcome were performed using cases
without any missing values (complete case analysis), as well as using
all cases completed by multiple imputation analysis of missing area
under the curve of the DEX-CRH test (SAS version 9.1) [22]. The
following quantities were included in the multiple imputations: age,
sex, BMI-1, HAMD-1, HAMD-2, nScale-1, nScale-2, NEON-1,
NEON-2, YearEducation, corAUCtotal-1, corAUCtotal-2, salivar-
yCorAUCtotal-1, salivaryCorAUCtotal-2, ActhAUCtotal-1, ActhA
UCtotal-2, and Intervention. To normalize the quantities during
the imputations the followingtransformations were done: age, BMI-
1, and all areas were log transformed, HAMD-1 and HAMD-2,
nScale-1, and nScale-2 were square root transformed. The
transformations y1=1/NEON-1
2 and y2=1/1/NEON-1
2 were
used to transform NEON-1 and NEON-2. Since the results
obtained using complete case analysis and those obtained using
analysis of 10 sets of imputed data were almost identical we only
report the results of the complete case analysis.
Results
Participants and non-participants characteristics
The probands (N=466) gave us permission to contact 359 first-
degree relatives, who were the potential participants in the trial.
The CONSORT participant flow diagram is shown in Figure 1. A
total of 80 participants, 29 (36%) women and 51 (64%) men were
included and randomized. The clinical and demographic
characteristics of the participants can be seen in Table 2.
The mean age of the non-participants was 37 (SD 11) years and
58% were women. The reasons for their non-participation are
presented in Figure 1.
The success of blinding
The agreement between the actual intervention group and the guess
was ‘some’ demasking (k=0.23 (0.01–0.45)) for the participants and
‘slight’ demasking (k=0.18 (0.00–0.40)) for the principal investigator.
Adherence to the intervention and adverse events
The validity of the results depended on a high compliance and
high completion in the trial. This was sought obtained by weekly
telephone control calls to the enrolled participants to insure
adherence to the protocol and to record adverse events. Two
participants randomized to escitalopram were excluded from the
trial prior to intervention: one man withdrew informed consent,
and one woman developed skin rash necessitating glucocorticos-
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the escitalopram group and 32 in the placebo group stated full
compliance with the protocol. Six participants in the escitalopram
group and seven in the placebo group stated that they missed
taking one or two tablets. No severe adverse reactions, or serious
adverse events occurred. Following four weeks of intervention,
56% of the participants in the placebo group and 46% of the
participants in the escitalopram group, reported no side effects.
Adverse events are listed in Table 3.
Plasma escitalopram
Blood was drawn from all 78 participants at follow up, but one
test from the escitalopram group failed. The mean concentration
of escitalopram was 50 nmol/l, SD 29 nmol/l, median 48 nmol/l,
range ,10 to 138 nmol/l, (N=38). Two participants from the
escitalopram group had undetectable plasma escitalopram, thus
,10 nmol/l, one of which had stated missing the last two tablets
prior to blood sampling. Plasma escitalopram was undetectable in
all participants of the placebo group.
Cortisol and ACTH response in the DEX-CRH test
The two datasets for the DEX-CRH test were complete for 73
participants. Thus, two participants had notests. Further, one woman
and one male missed the baseline test due to schedule problems. The
test following the intervention was missed by two males due to
schedule problems and one male due to technical reasons.
Figure 1. Flowchart for the AGENDA trial.
doi:10.1371/journal.pone.0021224.g001
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outcome DCorAUCtotal comparing the intervention and the
placebo groups, (p=0.47), (Table 4).
In univariate analyses, no statistically significant correlations
were found between DCorAUCtotal and the variables: age, sex,
HAM-D, body mass index, and number of daily cigarettes at
randomization (results not presented). We found no significant
differences between the results of the complete-case analysis and
the analysis done after multiple imputations (results not presented).
The correlation between plasma escitalopram and DCor-
AUCtotal were analyzed in the escitalopram group. Increasing
plasma escitalopram was significantly correlated with decreasing
DCorAUCtotal, (Friedmanns rho=20.41 (R
2=0.046), p=0.01).
Post-hoc explorative analyses
The escitalopram group and the placebo group did not separate
significantly in analyses of Dplasma ACTH AUCtotal, DCorBASAL, or
DCorPEAK, Table 4. In additional analyses we found that the
logarithm of AUCtotal for plasma cortisol before and after the
intervention followed a normal distribution with good approxi-
mation. Thus, the measure: DlogCorAUC=ln(CorAUCtotal.after)2ln
(CorAUCtotal.before)=ln(CorAUCtotal.after/CorAUCtotal.before)=ln(ratio),
which has a normal distribution, was analyzed. The means of
DlogCorAUC for escitalopram versus placebo did, however, not differ
significantly, (p=0.49),Table4.
There was a statistically significant interaction for DlogCorAUC
between age and intervention group. Thus, the slope relating to
age DlogCorAUC, (p=0.024) differed significantly between the
two intervention groups and the correlations between age and
DlogCorAUC were R
2=0.07, (Pearson’s rho=20.27), for
escitalopram and R
2=0.08, (Pearsons’s rho=0.28) for placebo,
thus the escitalopram was associated with decrease in the HPA-
response in the DEX-CRH test and this association increased with
age.
Data were moreover analyzed using mixed model effect
analyses. No statistically significant main effect of the intervention
(p=0.37) was noted and the intervention did nor influence the
locations (p=0.54) nor the slopes (p=0.98) of the three linear
functions (see Figure 2) significantly. In accordance with Modell
et al. [2], a subgroup of 23 individuals with a PEAK cortisol
concentration of 110 nmol/l or more in the DEX-CRH test at
trial entry was analyzed. No statistically significant difference was
shown on the DCorAUCtotal for this subgroup, (p=0.9). In
addition, we analyzed the effect of escitalopram on DCorAUCtotal
for participants of the escitalopram group that had detectable
escitalopram in plasma (N=36) versus placebo, but no statistically
significant difference was found, (p=0.69).
Discussion
The AGENDA trial is the first trial in which the effect of SSRI
in healthy first-degree relatives of patients with depression has
been investigated. Additionally, the AGENDA trial is the largest
trial hitherto (N=80) in which the effect of SSRI is investigated in
healthy individuals regardless of outcome [21]. The main finding
was that four weeks of intervention with escitalopram 10 mg/day
compared with placebo had no statistically significant effect on
neuroendocrine responses in the HPA-axis, as measured by
DCorAUCtotal in the DEX-CRH test, in healthy first-degree
relatives of patients with MDD. Thus, our hypothesis that an
intervention with escitalopram 10 mg would decrease the cortisol
response in DEX-CRH test in healthy first-degree relatives of
patients with MDD was not supported. Further, no statistically
significant effect was found on any other measure of the DEX-
CRH test (Table 4). Post-hoc analyses showed that increasing
Figure 2. The mean of ln (p-cortisol/unit) versus time in the placebo group (squares) and in the escitalopram group (triangles). For
each of the time intervals [1#time#5], [6#time#9] and [10#time#17] there is an approximate linear relationship between time and mean values.
doi:10.1371/journal.pone.0021224.g002
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DEX-CRH test and this effect increased with age.
Advantages of the trial
The AGENDA trial has several advantages. Firstly, the trial and
the analyses were carried out as planned in advance and the
completion and compliance in the trial was very high. Secondly,
the registered diagnosis of depression for the probands was verified
by a face-to-face psychiatric research interview by trained medical
doctors. The participants were assessed and diagnosed by
validated and frequently used multi-dimensional methods. Third-
ly, the participants were genetically homogeneous as all were
Table 2. Characteristics of participants at entry.
Characteristic Escitalopram (N=41) Placebo (N=39) All Participants (N=80)
Age – yr, mean 6 SD 32611 31611 32610
Women – N (%) 15 (37) 14 (36) 29 (36)
Proband was / – N (%)
sibling 18 (44) 15 (39) 33 (41)
parent 23 (56) 24 (62) 47 (59)
Caucasian – (%) 100 100 100
Education – mean 6 SD
Years of school 11611 1 611 1 61
Years of further education 3623 623 62
Employment status – N (%)
Employed 30 (73) 26 (67) 56 (70)
Student 11 (27) 11 (28) 22 (28)
Unemployed 0 (0) 2 (5) 2 (3)
Marital status – N (%)
Single 15 (37) 23 (59) 38 (48)
Married or cohabiting* 26 (63) 16 (41) 42 (52)
First degree relatives of patient with a
history of major depressive disorder
……………..– median (quartiles)**
1 (1;2) 1 (1;2) 1 (1;2)
Second degree relatives with a history
of major depressive disorder – median
(quartiles)
0 (0;1) 0 (0;1) 0 (0;1)
17-item Hamilton Depression Scale
Score, . – median (quartiles) (range)
1 (0;3) (0–7) 1 (0;3) (0–7) 1 (0;3) (0–7)
14-item Hamilton Anxiety Scale
Score, – median (quartiles) (range)
1 (0;2)… (0–9) 1 (0;2) (0–6) 1 (0;2) (0–9)
Beck Depression Inventory, 21-item,
depression median (quartiles)
2 (0;4) 2 (0;3) 2 (0;5)
Beck Depression Inventory, 14-item,
anxiety – median (quartiles)
1 (0;4) 2 (0;3) 1 (0;3)
Body Mass Index – kg/m
2, mean 6 SD 25642 6 652 6 64
Numbers of daily cigarettes - median
(quartiles)
0 (0;11) 0 (0;10) 0 (0;10)
Package years – median (quartiles) 1 (0;10) 2 (0;7) 1.75 (0;8)
Daily medicine – N (%) 2 (5) 4 (10) 6 (8)
Plasma cortisol AUCtotal - nmol/l6min/l,
mean 6 SD, median (quartiles)
9045612829
4691 (2864;8277)
15126617542
9974 (2549;18336)
12005615506
5095 (2669;13833)
Plasma ACTH AUCtotal - pmol/l6min/l,
mean 6 SD, median (quartiles)
3246272
255 (209;304)
3656197
306 (233;426)
3436239
263 (215;263)
Plasma cortisol BASAL - nmol/l,
mean 6 SD, median (quartiles)
15615
13 (8;17)
24637
15 (10;20)
19628
14 (9;18)
Plasma cortisol PEAK - nmol/l,
mean 6 SD, median (quartiles)
906124
41 (22;82)
1376153
86 (19;191)
1126140
52 (20;136)
Notes: Two smoked cannabis more than two months prior to the investigation. Three were previously abusing alcohol. One participant had generalized anxiety.
*Eight were living with their parents.
**quartiles reported, are the 25 and 75 quartiles.
There was no statistically significant difference (p.0.05) between the escitalopram and the placebo group for any of the hormone measures. AUCtotal=Area under the
curve after administration of CRH corrected for baseline equivalent, BASAL=mean of five measurements at the baseline after pre-treatment with deametasone 1.5 mg
and before the administration of CRH, PEAK=the highest measurement following CRH administration.
doi:10.1371/journal.pone.0021224.t002
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grandparents. Fourthly, we used well established methods, e.g.,
the DEX-CRH test which is a sensitive, biological, objective test to
detect increased HPA-function in humans [1,32]. The response to
the DEX-CRH test may be sensitive to age [32] and sex [33], and
in our trial, stratification by these factors resulted in equal
distributions in the two intervention groups. Fifthly, the partici-
pants were studied in a randomized clinical trial blinded in all
phases including the statistical analyses and conclusion phase. The
blinding was successful in relation to participants as well as
researchers. Finally, the antidepressant effect of escitalopram is
generally accepted [14] and the participants were subjected to four
weeks of intervention thus including the interval in which clinical
improvement has been reported in trials with patients with MDD
[14].
Limitations
We have not compared healthy individuals with a family history
of MDD to healthy individuals without a family history of MDD.
However, the participants included in the present trial presented
with values of CorAUCtotal in the initial DEX-CRH test before
intervention, (Table 2 (12,005615,506 nmol/l6min/l)) that were
higher than values found among healthy individuals without a
family history of MDD in the study by Modell et al. [2]
(7,77361,071 nmol/l6min/l) and approaching the values for
healthy individuals with a family history of MDD in that study
(1506463947 nmol/l6min/l), suggesting that participants includ-
ed in our trial were comparable to the participants with a family
history of depression in the Modell study. Notably, our results
showed rather large intra- and interindividual variation in the
baseline cortisol response to the DEX-CRH test as well in the
change in the cortisol response from start to end of intervention,
Tables 2 and 4. It cannot be excluded that the quality of the
detective methods in the DEX-CRH test as well as the
heterogeneity of the individuals included in the trial may have
added to the increase in the variability of the DEX-CRH response.
For example, the experimental situation of the DEX-CRH test
may influence individuals in different ways resulting in a variation
of the DEX-CRH response. However, this was a randomized trial
and such unknown confounders ought to be evenly distributed
between the escitalopram and the placebo group.
We cannot exclude that the dosage of 10 mg escitalopram was
too low. However, this dosage has been suggested as the optimum
dose for treatment of moderate depression [34] and it resulted in
well-known adverse effects (Table 3), thus a substantial proportion
of the participants in the escitalopram group reported sexual
Table 3. Assessed adverse events by the UKU Side Effect
Rating Scale for 78 healthy first degree relatives of patients
with a history of major depressive disorder following four
weeks of intervention by escitalopram 10 mg (N=39) or
placebo (N=39) in the AGENDA trial.
Adverse events
Escitalopram
N (%) Placebo N (%) p (x
2)
Restlessness 6 (15) 9 (23) 0.39
Insomnia 2 (5) 9 (23) 0.02*
Tremor 1 (3) 1 (3) 1.00
Nausea 4 (10) 4 (10) 1.00
Diarrhoea 4 (10) 1 (3) 0.17
Sweating 6 (15) 4 (10) 0.50
Less libido 7 (18) 2 (5) 0.08
Erective
dysfunction (men)
5 (13) 1 (3) 0.09
Ejaculating
problems (men)
11 (28) 1 (3) 0.002*
Orgasmic
dysfunction
11 (28) 0 (0) 0*
Headache 1 (3) 1 (3) 1.00
doi:10.1371/journal.pone.0021224.t003
Table 4. The distributions of the primary outcome measure and other characteristics of plasma cortisol and plasma ACTH in the
combined DEX-CRH test in 73 healthy first-degree relatives of patients with a history of major depressive disorder, in the
escitalopram 10 mg group (N=38) and the placebo group (N=35).
Quantity Group (N) Mean (SD) Median Minimumvalue
Maximum
value
Interquartile
range p
b)
Dplasma cortisol AUCtotal
a) Escitalopram 1675.1 (13001) 606.6 240895.6 47913.8 8782.6 ……0.47
Placebo 1170.5 (17910) 2200.0 244680.2 56859.7 7064.2
Dplasma ACTH AUCtotal Escitalopram 25.1 (158) 20.08 2392.0 653.0 67.1 ……0.23
Placebo 26.48 (255) 210.7 2750.0 743.0 108.0
Dplasma cortisol BASAL Escitalopram 0.461 (13.5) 20.345 225.4 72.9 4.60 ,,,,,,,0.57
Placebo 5.17 (48.4) 0.340 2363 84.1 5.49
Dplasma cortisol PEAK Escitalopram 3.96 (124) 23.92 2348 356 80.0 ,,,,,,,0.61
Placebo 1.76 (131) 1.23 2348 422 69.7
ln (totalAUCafter/totalAUCbefore) Escitalopram 0.039 (1.039) 0.147 22.69 2.75 *20.611 20.292 ,,,,,,,0.48
Placebo 20.120 (0.895) 20.0265 23.40 1.11 *20.614 20.294
D was the difference between the measurement of plasma cortisol and ACTH after and before four weeks of intervention with escitalopram 10 mg or placebo for:
AUCtotal=Area under the curve after administration of CRH corrected for baseline equivalent, BASAL=mean of five measurements at the baseline after pre-treatment
with dexametasone 1.5 mg and before the administration of CRH, PEAK=the highest measurement following CRH administration,
a)Dplasma cortisol AUCtotal was the primary outcome measure.
b)p of Mann-Whitney test comparing the two distributions which did not follow normal distributions (Shapiro Wilkes test).
*95% C.I. are reported since the distributions followed normal distributions.
doi:10.1371/journal.pone.0021224.t004
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pram group.
Risk of errors
The risk of errors in trials falls in three major categories [35,36]:
1) Systematic error (‘bias’): We have minimized bias by using a
randomized, age-and sex-stratified, comparison with blinding in
all phases of the trial. 2) Random error (‘play of chance’): We planned
to include 80 participants due to resources, feasibility, and
availability of the healthy first-degree relatives of patients with
MDD studied in our group. Since no prior trials have investigated
the effect of SSRI on healthy individuals, the power calculations
were hypothetical and influenced by great uncertainty. Thus, we
cannot exclude the possibility of overlooking a difference due to
the play of chance. However, in the era of systematic reviews it has
been questioned if the size of an individual trial still does matter
[35]. The results from any trial may contribute to the larger body
of evidence despite arbitrary sample size calculations in the
individual trial that may eventually prevent important trials from
being conducted [37]. 3) Design errors: These errors may include
that some participants may not have reached sufficient levels of
escitalopram in the blood in order to produce an effect on the
HPA-axis. Our serum escitalopram concentrations were lower
than in a study by Soegaard et al. [38], who found steady state
plasma escitalopram concentrations of 63632 nmol/l for escita-
lopram 10 mg as compared to 50629 nmol/l in our trial. The low
plasma levels in our trial may be a result of the fact that
approximately 12 hours elapsed from taking the last tablet to
blood sampling and that the half-life of escitalopram is 27–
32 hours. However, a therapeutic plasma interval level has never
been clearly defined for escitalopram. The intervention time is
considered to be appropriate since clinical improvement is seen
within this time, however it cannot be excluded that an effect of
escitalopram could be detected in a trial with longer duration.
Generalizability, clinical implication and future studies
Our participants were healthy, ethnic Danes, with a parent or a
sibling who was treated for depression in a hospital setting in
Denmark. Our results may generalize to healthy Caucasians in
general. To infer direct clinical implications from the results were
not an aim of our trial, but effects by escitalopram 10 mg on the
primary outcome for the HPA-axis function in healthy was not
detected. Future studies may explore individuals in prodromal
phases of depressive disorder or establish a run in period to
optimize adherence to protocols. Further, the distinction between
healthy participants with and without increased familial risk for
MDD needs further exploration.
Interpretation
Considering advantages, disadvantages, risk of errors, and
generalizability of the findings in this trial, it is likely that the
results reflect reality. Thus, activation of the monoaminergic
neurotransmitter systems by escitalopram does not seem to
substantially affect the HPA-axis as measured by the DEX-CRH
test in healthy individuals with a family history of depression. This
finding seems to indicate that intervention with SSRI does not
reduce the response to stress, as induced by CRH in the DEX-
CRH test, in first-degree relatives. Our finding is in accordance
with recent data showing that restoration of HPA system
dysfunction seems to be neither a necessary nor a sufficient
determinant for an acute treatment response in depressed patients
[39]. Taken together these findings suggest that dysregulation of
the HPA-axis, as assessed by the DEX-CRH test, does not play a
primary role in the mechanisms of action of SSRIs. The HPA
dysregulation seen in depressed patients may rather represent the
down stream effects of other, more primary abnormalities as
suggested by Manji et al. [40].
In conclusion, the AGENDA trial is the first to investigate the
effect of a long-term intervention with escitalopram on serotonin-
mediated HPA-axis responses in healthy first-degree relatives of
patients with MDD. The results did not show a statistically
significant difference in DCorAUCtotal in the DEX-CRH test
between escitalopram 10 mg and placebo given for four weeks.
Further, the results showed large intra- and inter-individual
differences in the response to the DEX-CRH test. Increasing drug
levels of escitalopram was associated with a decrease in the HPA-
response of the DEX-CRH test and this association increased with
age.
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